Fred Alger Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Fred Alger Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-243,004	Closed	-$14.7M	–	800
2014 Q4	$14.7M	Buy	243,004 +130,229	+115%	+$6.54M	0.07%	209
2014 Q3	$4.8M	Sell	112,775 -40,028	-26%	-$2.15M	0.02%	343
2014 Q2	$9.44M	Sell	152,803 -25,173	-14%	-$1.46M	0.05%	298
2014 Q1	$11.6M	Sell	177,976 -1,543	-0.9%	-$104K	0.06%	290
2013 Q4	$10.1M	Buy	179,519 +33,266	+23%	+$1.87M	0.05%	297
2013 Q3	$8.96M	Sell	146,253 -404	-0.3%	-$27.4K	0.05%	299
2013 Q2	$8.57M	Buy	+146,657	New	+$9.02M	0.05%	302

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fred Alger Management's OREX Position: Q1 2015 in Review

Fred Alger Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2015, closing a stake of 243,004 shares — an estimated $14.7M sold.

Fred Alger Management first reported a position in OREX in Q2 2013 and held it in 7 quarters. The position peaked at $14.7M in Q4 2014. 160 funds tracked by Wall St. Rank hold OREX as of Q1 2015.

Fred Alger Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Fred Alger Management sold 243,004 Orexigen Therapeutics, Inc. shares in Q1 2015, an estimated $14.7M.
Fred Alger Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 7 quarters.
Fred Alger Management's Orexigen Therapeutics, Inc. position peaked at $14.7M in Q4 2014.
160 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2015.

Based on Fred Alger Management's 13F filing for Q1 2015, filed 15 May 2015.